PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ADHD medicine affects the brain's reward system

A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system

2012-11-09
(Press-News.org) A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system. The model makes it possible to understand the effect of the medicine and perhaps in the longer term to improve the development of medicine and dose determination. The new research results have been published in the Journal of Neurophysiology.

In Denmark approximately 2-3 per cent of school-age children satisfy diagnostic criteria for ADHD, and therefore it is crucial to know how the medicine works. With a new mathematical reconstruction of a tiny part of the brain region that registers reward and punishment, scientists from the University of Copenhagen are acquiring new knowledge about the effect of ADHD medicine. When reward and punishment signals run through the brain, the chemical dopamine is always involved.

"It has been discussed for years whether treating ADHD with Ritalin and similar drugs affects the reward system to any significant degree, simply because the dosage given to patients is so low. We are the first to show that some components of the dopamine signalling pathways are extremely sensitive to drugs like Ritalin. We have also developed a unified theory to describe the effect of such drugs on the dopamine signal," says Jakob Kisbye Dreyer, postdoctoral candidate at the Department of Neuroscience and Pharmacology, Faculty of Medical and Health Sciences, University of Copenhagen, where the model was developed.

He emphasises the importance of knowing exactly what happens during treatment with drugs like Ritalin. This is in order to develop better and more targeted medicine, as well as to understand the psychology underlying ADHD. The actions of human beings are motivated by an unconscious calculation of cost relative to expected gain. The scientists' results show that ADHD medicine specifically reduces signals about anticipated punishment.

Reward and punishment

In the brain, dopamine contributes to series of processes that control our behaviour. Actions such as eating, winning a competition, having sex or taking a narcotic drug increase dopamine release. Scientists think that dopamine helps motivate us to repeat actions that have previously been associated with reward.

"Control mechanisms in the brain help keep the dopamine signal in balance so we can register the tiny deviations that signal reward and punishment. We discovered while trying to describe these control mechanisms that our model can be used to examine the influence of Ritalin, for example, on the signal. Suddenly we could see that different pathways of the reward system are affected to different degrees by the medicine, and we could calculate at what dosage different parts of the signal would be changed or destroyed," says Jakob Kisbye Dreyer.

Different dosage, different effect

Drugs such as Ritalin can have paradoxical effects: high dosage increases the patient's activity while low dosage reduces it. Therefore it can be a laborious process to find the right dosage for a patient.

"We can explain this double effect using our theory. The dopamine signal in the part of the brain that controls our motor behaviour is only affected at a higher dose that the dose usually prescribed for treatment. Also, our model shows that the threshold between a clinically effective dose and too high a dose is very low. That may explain why the small individual differences between patients have a big impact on treatment," says Jakob Kisbye Dreyer.

In the long term, the scientists hope that their new insight will help doctors determine the correct dose for each patient. The model can also help us understand what signals in the brain affect not only ADHD, but schizophrenia, Parkinson's disease and drug abuse as well.

### Read the article in the Journal of Neurophysiology.

Contact

Postdoc Jakob Kisbye Dreyer
Department of Neuroscience and Pharmacology
Faculty of Health and Medical Sciences
Phone: +45 6080 9551
E-mail: jakobdr@sund.ku.dk


ELSE PRESS RELEASES FROM THIS DATE:

New mechanism of action for PARP inhibitors discovered

2012-11-09
PHILADELPHIA — New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has led to the identification of ways in which the patient population that might benefit from PARP inhibitors could be expanded. Yves Pommier, M.D., Ph.D., chief of the Laboratory of Molecular Pharmacology at the National Cancer Institute's Center for Cancer Research in Bethesda, Md., and colleagues reported these data in Cancer Research, a journal ...

Link found between child prodigies and autism

2012-11-09
COLUMBUS, Ohio - A new study of eight child prodigies suggests a possible link between these children's special skills and autism. Of the eight prodigies studied, three had a diagnosis of autism spectrum disorders. As a group, the prodigies also tended to have slightly elevated scores on a test of autistic traits, when compared to a control group. In addition, half of the prodigies had a family member or a first- or second-degree relative with an autism diagnosis. The fact that half of the families and three of the prodigies themselves were affected by autism is surprising ...

Study questions the relevance of SCIP benchmarks among CABG patients

2012-11-09
(Boston) – Cardiothoracic surgeons and endocrinologists from Boston Medical Center (BMC) have found that among patients undergoing coronary artery bypass graft (CABG) surgery, achieving Surgical Care Improvement Project (SCIP) benchmarks for glycemic control may be irrelevant when perioperative continuous insulin infusion protocols are implemented. These findings appear on-line in the Journal of Thoracic and Cardiovascular Surgery. Currently, 40 percent of all patients undergoing CABG suffer from diabetes, and this number is quickly rising. Traditionally these patients ...

Belatacept after a kidney transplant: Minor added benefit for certain patients

2012-11-09
Belatacept (trade name Nulojix®) has been approved since June 2011 to prevent a rejection reaction of the body to the donor organ (transplant) in adults who have received a kidney transplant. The Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG). The assessment showed an indication of a minor added benefit of belatacept in adults with transplants from donors who had been selected according to the so-called standard criteria. Serious side ...

Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors

2012-11-09
Researchers at Moffitt Cancer Center have identified metabolic signatures that may pave the way for personalized therapy in glioma, a type of tumor that starts in the brain. The study appears online in the October issue of Cancer Research, a publication of the American Association for Cancer Research. According to the authors, little has been known about the underlying metabolic alterations that may drive the growth of the most aggressive type of glioma, termed glioblastoma. "For the first time, we have described global metabolomic signatures in glioma," said study ...

Considerable added benefit of ipilimumab in advanced melanoma

2012-11-09
The humanized antibody ipilimumab (trade name Yervoy®) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means that the melanoma can no longer be removed by an operation or that metastases have formed. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, the drug offers major advantages with ...

University of Huddersfield physicist investigates the Big Bang particle

2012-11-09
Scientists at the University of Huddersfield are collaborating with experts at some of the world's leading research institutes in an attempt to unravel the mysteries of a particle that played a role in the creation of the universe. The existence of neutrinos and anti-neutrinos – particles that are almost massless and which travel at light speed from one side of the earth to the other – was confirmed more than 50 years ago. Scientists believe that they were created at the Big Bang and might hold the key to the nature of the universe. But they are light particles that ...

Vandetanib in thyroid cancer: No proof of added benefit

2012-11-09
Vandetanib (trade name Caprelsa®) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, because no data on patient-relevant outcomes for those patients for whom the drug is approved were presented by the drug manufacturer in its dossier. ...

UGR and Michael J. Fox Foundation take a step forward in the study of Parkinson's disease

2012-11-09
This press release is available in Spanish. During the past year, the research group TIC 218 at the Department of Signal Theory, Telematics and Communications attached to the University of Granada and the Andalusian Information Technology and Communications Center (CITIC) has implemented the methods for the detection and diagnosis of Alzheimer's disease, within the PPMI initiative of the Michael J. Fox foundation for the study of Parkinson's disease. In addition, other databases were used such as that of the Virgen de la Victoria Hospital, Málaga, Spain, and Virgen de ...

CHOP experts describe research in pediatric heart disease

2012-11-09
Physician-researchers from the Cardiac Center at The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions 2012 in Los Angeles. They described racial disparities in risk factors for sudden cardiac death, imaging modalities and novel approaches to assessing cardiac anomalies, ventricular assist device use, special considerations in syndromes in adult congenital heart disease, changes in immunosuppressive drugs after pediatric heart transplant, and many other topics. Children's ...

LAST 30 PRESS RELEASES:

Sex differences drive substance use patterns in panic disorder patients

Multi-omics meets immune profiling in the quest to decode disease risk

Medication-induced sterol disruption: A silent threat to brain development and public health

Shining a light on DNA: a rapid, ultra-sensitive, PCR-free detection method

European hares are thriving in the city: New monitoring methods reveal high densities in Danish urban areas

Study: middle-aged Americans are lonelier than adults in other countries, age groups

World’s leading science competition identifies 19 breakthrough solutions around the globe with greatest potential to tackle the planetary crisis

Should farm fields be used for crops or solar? MSU research suggests both

Study: Using pilocarpine drops post goniotomy may reduce long-term glaucoma medication needs

Stanford Medicine researchers develop RNA blood test to detect cancers, other clues

Novel treatment approach for language disorder shows promise

Trash talk: As plastic use soars, researchers examine biodegradable solutions

Using ChatGPT, students might pass a course, but with a cost

Psilocibin, or “magic mushroom,” use increased among all age groups since decriminalization in 2019

More Americans are using psilocybin—especially those with mental health conditions, study shows

Meta-analysis finds Transcendental Meditation reduces post-traumatic stress disorder (PTSD) symptoms across populations and cultures

AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards

How not to form a state: Research reveals how imbalanced social-ecological acceleration led to collapse in early medieval Europe

Introduced trees are becoming more common in the eastern United States, while native diversity declines

The chemical basis for life can form in interstellar ice

How safe is the air to breathe? 50 million people in the US do not know

DDT residues persist in trout in some Canadian lakes 70 years after insecticide treatment, often at levels ten times that recommended as safe for the wildlife which consumes the fish

Building ‘cellular bridges’ for spinal cord repair after injury

Pediatric Academic Societies awards 33 Trainee Travel Grants for the PAS 2025 Meeting

Advancing understanding of lucid dreaming in humans

Two brain proteins are key to preventing seizures, research in flies suggests

From research to real-world, Princeton startup tackles soaring demand for lithium and other critical minerals

Can inpatient psychiatric care help teens amid a depressive crisis?

In kids, EEG monitoring of consciousness safely reduces anesthetic use

Wild chimps filmed sharing ‘boozy’ fruit

[Press-News.org] ADHD medicine affects the brain's reward system
A group of scientists from the University of Copenhagen has created a model that shows how some types of ADHD medicine influence the brain's reward system